乳腺隐匿性病灶的微创活检

目的:探讨X线立体定位下核芯针穿刺活检(SCNB)对乳腺隐匿性病灶(NPBL)的临床应用价值。方法:运用乳腺X线立体定位系统对59例NPBL进行SCNB,其中42例行手术切除,将活检标本病理结果与X线表现、手术标本病理结果进行对照。结果:59例SCNB结果中良性病变43例,恶性病变16例(导管原位癌5例、浸润性导管癌11例),其中26例良性病变及16例恶性病变共42例行手术治疗,术后病理结果为良性病变25例,恶性病变17例(导管原位癌5 例、浸润性导管癌11例、硬癌1例)。与手术病理结果对照,SCNB对NPBL的诊断敏感度为94％,特异度为100％。结论:SCNB是诊断NPBL简便、实用、微创的方法,可获得准确的组织病理学结果,提高早期乳腺癌的检出率及降低良性病变的手术活检率。     

超声检查对肉芽肿性小叶性乳腺炎和乳腺浸润性导管癌的鉴别诊断价值

目的 探讨超声检查在肉芽肿性小叶性乳腺炎（granulomatous lobular mastitis,GLM）和乳腺浸润性导管癌（invasive ductal carcinoma, IDC）鉴别诊断中的价值。方法 选取48例GLM与89例IDC患者的彩色多普勒超声资料，并与病理结果进行对照分析。结果 GLM组病灶的边缘毛刺或蟹足征、微小钙化、后方回声衰减的检出率低于IDC，差异有统计学意义（P<0.05），伴液性无回声和周边高回声晕的检出率高于IDC，差异有统计学意义（P<0.05）。两组病灶在伴腋窝淋巴结肿大和血流分级上差异无统计学意义（P>0.05）。结论 GLM声像图表现具有一定特征性，伴液性无回声及周边高回声晕的超声检查征象与IDC有所不同。故超声检查对GLM和IDC的鉴别诊断有价值。     

钼靶X线定位穿刺留置导丝活检对乳腺微小病灶的诊断价值

目的探讨乳腺X线定位穿刺留置导丝活检术对乳腺微小病灶的诊断价值。方法回顾分析临床触诊阴性而乳腺钼靶X线片显示的微小病灶28例,采用乳腺钼靶X线定位下穿刺,留置导丝于微小病灶区,引导手术将病灶切除活检。结果28例微小病灶均一次性定位成功,定位满意率93%,手术切除完整。病理检查:恶性病变9例,其中浸润性导管癌5例,导管内癌伴早期浸润1例,导管内癌2例,髓样癌1例;良性病变19例。结论乳腺钼靶X线定位穿刺留置导丝活检术,定位准确,诊断明确,能确定乳腺微小病灶的性质,是目前诊断早期乳腺癌的有效方法。     

MRI引导乳腺活组织穿刺检查的初步研究

目的:探讨在MRI引导下行乳腺穿刺活检的可行性和临床适应证。材料和方法:采用自制的乳腺固定架,用模型完成乳腺固定架空间定位精确度测试后,为9例志愿者进行临床测试。9例志愿者的病灶均评价为BI-RADS3～5级,其中8例为超声和钼靶不能显示的病灶。使用Mammotome真空辅助穿刺装置,从影像学、外科学和病理学的角度对MRI引导乳腺病变穿刺活检的可行性进行评价。结果:5次模型测试的平均误差为2.2±0.63mm,穿刺精度符合要求。9例病人均成功完成穿刺操作,病理证实1例为不典型导管上皮增生(随访手术完全切除),1例乳腺导管原位癌(ductal carcinoma in situ,DCIS;后续手术切除),2例导管内乳头状瘤(1例全切,1例多发只切除单个病灶),1例窦样血管增生,1例腺瘤部分切除,3例腺病或增生。结论:MRI引导的乳腺活检具有影像学、外科学和病理学方面的可行性,能为钼靶和超声不能检测的病灶提供活检确诊的手段。     

超声检查与MRI诊断乳腺浸润性微乳头状癌临床价值分析

目的 探讨超声检查与MRI对乳腺浸润性微乳头状癌(invasive micropapillary carcinoma,IMPC)的诊断价值.方法 选取63例女性IMPC患者,均经病理学检查证实,设置为IMPC组.另于同期选取40例浸润性导管癌患者(IDC组)进行诊断效能对照.结果 单独超声检查诊断的准确度、灵敏度、特异...     

剪切波弹性成像对于穿刺活检诊断为导管内原位癌的病人升级为侵袭性乳腺癌的预测价值

正摘要目的评价剪切波弹性成像(SWE)测量的肿块硬度能否预测超声引导下粗针穿刺活检(CNB)诊断的导管内原位癌(DCIS)的组织学升级。方法本研究经机构伦理委员     

全视野数字化乳腺摄影对乳腺导管原位癌的诊断价值

目的 :探讨全视野数字化乳腺摄影(full-field digital mammography,FFDM)对乳腺导管原位癌(ductal carcinoma in situ,DCIS)的诊断价值。方法 :选择经手术病理证实的DCIS患者36例,分析其X线表现。患者术前均行FFDM检查。诊断标准采用美国放射学院(ACR)推荐的乳腺影像报告和数据系统(BI-RADS)。结果:病灶出现钙化23例;肿块16例,其中肿块伴钙化5例;局灶性致密伴钙化11例;结构扭曲伴钙化7例;阴性1例;致密乳腺建议其他检查1例。BI-RADS诊断:5类11例,4类19例,3类3例,2类、1类、0类各1例。FFDM诊断的敏感性91.67%,符合率83.33%。结论:DCIS的常见X线表现为恶性钙化、肿块,FFDM对乳腺DCIS有重要的诊断价值。     

DBT联合FFDM、FFDM对乳腺疾病诊断效能比较

浸润性导管癌(invasive ductal carcinoma,IDC)为最常见的乳腺癌之一,浸润性生长,具有明显转移倾向.与乳腺超声、乳腺CT及MR相比,乳腺X线摄影在对乳腺内病灶的钙化数量、形态、大小及密度的显示方面具有明显优势;数字化乳腺摄影的出现使乳腺癌的早期检出率大大提高[1].而一些乳腺疾病诸如腺病、炎症等在X线摄影上常与恶性病变难以分辨.     

乳腺非肿块型病变的超声诊断

目的探讨乳腺非肿块型病变的超声表现,提高超声诊断率。资料与方法回顾性分析经手术或穿刺活检病理确诊的57例乳腺非肿块型病变的超声表现,并与病理结果进行对照。结果 57例非肿块型乳腺病变中,恶性病变39例(68.4%),非恶性病变18例(31.6%)。42例(73.7%)病变表现为片状低回声区,12例(21.1%)表现为含散在微钙化的片状低回声区,3例(5.3%)表现为散在或簇状分布的微钙化,后方伴或不伴声衰减。超声诊断的准确性为68.4%,敏感性为94.9%,特异性为11.1%,阳性预测值为69.8%,阴性预测值为50.0%。导管内癌微钙化比例(47.1%,8/17)显著高于浸润性导管癌(15.8%,3/19)(χ2=4.918,P<0.05)。恶性组腋下异常淋巴结的发生率显著高于非恶性组(χ2=4.503,P<0.05)。结论非肿块型乳腺病变多以含或不含微钙化的片状低回声及微钙化的形式表现,超声诊断敏感性较高,但特异性很低。病变内部微钙化的存在对于导管内癌的诊断具有一定意义。腋下是否存在异常淋巴结对于良恶性病变的鉴别诊断有一定帮助。     

超声引导下淋巴结经皮穿刺活检对颈部肿大淋巴结的诊断价值

目的 :探讨超声引导下淋巴结经皮穿刺活检术(percutafleous needle core biopsy,PNCB)对颈部肿大淋巴结诊断的应用价值。方法:选择104例颈部淋巴结肿大的患者,对其行常规超声检查、PNCB病理诊断及手术切除淋巴结病理诊断。统计进针次数、成功率、PNCB取材效果,并评价结果。将手术切除标本病理学检查结果为金标准,分为恶性(阳性)与良性(阴性),采用ROC分析方法计算常规超声与PNCB病理诊断的敏感度、特异度、阳性预测值、阴性预测值及准确率。结果 :104例均进针3~6次,共穿刺415针,其中386针适合进行病理学检查,成功率93.01%。415针穿刺取材效果评价分4级结果为:优202针,良141针,一般43针,差29针;术后病理学诊断显示,颈部淋巴结结核31例,炎性增生淋巴结5例,恶性淋巴瘤16例,转移或浸润癌52例。PNCB病理诊断除1例将转移癌诊断为炎性增生淋巴结外,其余病理诊断与术后病理学诊断一致;常规超声诊断敏感度97.06%、特异度75.00%、阳性预测值88.00%、阴性预测值93.10%、准确率89.42%,PNCB的病理诊断的敏感度98.53%、特异度100%、阳性预测值100%、阴性预测值97.36%、准确率99.04%。结论 :PNCB诊断颈部肿大淋巴结安全、易操作,且标本满意率及病理诊断准确性高,值得临床推广。     

Comparison of the underestimation rate in cases with ductal carcinoma in situ at ultrasound-guided core biopsy: 14-gauge automated core-needle biopsy vs 8- or 11-gauge vacuum-assisted biopsy

Objective

The objective of this study was to compare the underestimation rate of invasive carcinoma in cases with ductal carcinoma in situ (DCIS) at percutaneous ultrasound-guided core biopsies of breast lesions between 14-gauge automated core-needle biopsy (ACNB) and 8- or 11-gauge vacuum-assisted biopsy (VAB), and to determine the relationship between the lesion type (mass or microcalcification on radiological findings) and the DCIS underestimation rate.

Methods

We retrospectively reviewed imaging-guided biopsies of breast lesions performed from February 2003 to August 2008. 194 lesions were diagnosed as DCIS at ultrasound-guided core biopsy: 138 lesions in 132 patients by 14-gauge ACNB, and 56 lesions in 56 patients by 8- or 11-gauge VAB. The histological results of the core biopsy samples were correlated with surgical specimens. The clinical and radiological findings were also reviewed. The histological DCIS underestimation rates were compared between the two groups and were analysed for differences according to the clinical and radiological characteristics of the lesions.

Results

The DCIS underestimation rate was 47.8% (66/138) for 14-gauge ACNB and 16.1% (9/56) for VAB (p<0.001). According to the lesion type on sonography, DCIS underestimation was 43.4% (63/145) in masses (47.6% using ACNB and 15.8% using VAB; p=0.012) and 24.5% (12/49) in microcalcifications (50.0% using ACNB and 16.2% using VAB; p=0.047).

Conclusion

The underestimation rate of invasive carcinoma in cases with DCIS at ultrasound-guided core biopsies was significantly higher for ACNB than for VAB. Furthermore, this difference does not change according to the lesion type on ultrasound. Therefore, ultrasound-guided VAB can be a useful method for the diagnosis of DCIS lesions presented as either mass or microcalcification.Ductal carcinoma in situ (DCIS) is mostly presented as microcalcification on radiography. Therefore, previous reports regarding the accuracy of core biopsy in DCIS have mainly focused on stereotactic (ST) guidance [1-4]. With the development and introduction of high-resolution ultrasound, several reports have studied various applications of ultrasound on the core biopsy for breast lesions, including ultrasound-guided core biopsy for microcalcification [5-9] and ultrasound-guided vacuum-assisted removal [10]. Ultrasound guidance has several advantages over ST guidance: a lack of ionising radiation, use of non-dedicated equipment, real-time needle visualisation, multidirectional sampling, lower cost [8,11] and less patient discomfort [8,11-13]. For these reasons, ultrasound-guided core biopsy may be preferable in lesions that are amenable to core biopsy with both ST and ultrasound guidance.One critical issue in percutaneous biopsy for diagnosis of DCIS may be DCIS underestimation, which means the underestimation of invasive cancer in cases where the core biopsy shows DCIS [1]. As underestimated DCIS at the core biopsy is upgraded to invasive carcinoma at surgery, axillary node dissection at a later date and thus a two-stage therapeutic surgical procedure can be resulted in [1]. The DCIS underestimation rate in ST-guided core biopsy is generally 10–36% with a large number of cases. Among them, 11-gauge vacuum-assisted biopsy (VAB) is well known to show a significantly lower DCIS underestimation rate than 14-gauge automated core-needle biopsy (ACNB) under ST-guidance [1,14-16]. However, studies with ultrasound-guided core biopsy have not found significant differences in DCIS underestimation between ACNB and VAB [17-18]. Moreover, previous studies using ultrasound guidance included only a small number of cases, and it is not well established whether the biopsy device (ACNB or VAB) and lesion type (microcalcification or mass) would affect the underestimation rate under ultrasound guidance.The purpose of this study was to compare the underestimation rate of invasive carcinoma in cases with DCIS at ultrasound-guided core biopsies between 14-gauge ACNB and VAB, and to determine the relationship between lesion types (mass or microcalcification on radiological findings) and the DCIS underestimation rate.     

Management of radial scars found at percutaneous breast biopsy.

OBJECTIVE: To determine whether percutaneous biopsy can safely differentiate radial scars (RS) that can be followed from those that require excision. METHODS: Retrospective analysis of prospectively collected data regarding 15 986 biopsies was performed at the Centre Hospitalier de l'Université de Montreal between October 1995 and December 2003 and yielded 227 RS. The type of biopsy, number of cores, and mammographic characteristics were recorded. Only lesions with surgical pathology or 24 months of mammographic stability were considered for analysis. Subgroup analyses were performed for patients who underwent 14-gauge core biopsy (CB), 11-gauge vacuum-assisted biopsy (VAB), or both. RESULTS: Among the 14-gauge CBs (n = 176), data were available for 144 (81.8%); among the 11-gauge VABs (n = 51), data were available for 40 (78.4%). Thirty lesions had 14-gauge CB followed by 11-gauge VAB. RS were associated with cancer in 19.6%, with a high-risk lesion in 20.1% and a benign lesion in 60.3%. Overall, 4% of cancers were missed (5% for 14-gauge CB and 0% for 11-gauge VAB), and cancer was underestimated in 22.2% (25% for 14-gauge CB and 16.7% for 11-gauge VAB). One (3.7%) additional cancer was found when benign radial scar on 14-gauge CB underwent subsequent 11-gauge VAB. Cancer was associated with 37% of RS presenting as masses but with only 17.1% of distortions and 12.3% of microcalcifications. CONCLUSIONS: If benign radial scar is found on 14-gauge CB, further evaluation is needed with 11-gauge VAB or surgery. Our data support mammographic follow-up for RS that are benign on 11-gauge VAB.     

Stereotactic vacuum-assisted breast biopsy in 268 nonpalpable lesions

PURPOSE: We evaluated the reliability of stereotactic vacuum-assisted breast biopsies (VAB) from our personal experience. MATERIALS AND METHODS: Between January 2003 and December 2005, 268 patients underwent VAB with an 11-gauge probe at our institution. Inclusion criteria were nonpalpable lesions, undetectable by ultrasound and suspected at mammography (microcalcifications, circumscribed mass, architectural distortion), for which cytology and/or core biopsy could not provide a definite diagnosis. Lesion mammographic patterns were microcalcifications in 186 cases (77.5%), mostly localised clusters (130/186: 70%); circumscribed mass with or without microcalcifications in 36 cases (15%) and architectural distortion with or without microcalcifications in 18 cases (7.5%). On the basis of the Breast Imaging Reporting and Data System (BI-RADS) classification, 16 cases (7%) were graded as highly suspicious for malignancy (BI-RADS 5), 81 (34%) as suspicious for malignancy (BI-RADS 4b), 97 (40%) as indeterminate (BI-RADS 4a) and 46 (19%) as probably benign (BI-RADS 3). Lesion size was 20 mm in only 38 cases (16%), 30 of which appeared as microcalcifications. RESULTS: In 28/268 lesions (10.5%) the biopsy could not be performed (nonidentification of the lesion; inaccessibility due to location or breast size). In 12/240 (5%) biopsies, the sample was not representative. Pathology revealed 100/240 (42%) malignant or borderline lesions and 140/240 (58%) benign lesions. Among the malignant lesions, 16/100 (16%) were invasive carcinoma [infiltrating ductal carcinoma (IDC) or infiltrating lobular carcinoma (ILC)], 13/100 (13%) were microinvasive (T1mic), 35/100 (35%) were ductal carcinoma in situ (DCIS), 9/100 (9%) were lobular carcinoma in situ (CLIS). Among the borderline lesions, 27/100 (27%) were atypical epithelial hyperplasia [atypical ductal hyperplasia (ADH) or atypical lobular hyperplasia (ALH)]. In 9/100 surgically treated lesions (9%), there was discordance between the microhistological findings of VAB and the pathological results of the surgical procedure: 8/9 were underestimated by VAB (four ADH vs. DCIS, three DCIS vs. IDC, one ADH vs. IDC), and 1/9 was overestimated (T1mic vs. DCIS). Complications following VAB occurred in 9/240 patients (3.7%). CONCLUSIONS: In our experience, VAB showed fair reliability in the diagnosis of nonpalpable breast lesions despite a portion of failed (10.5%), nonsignificant (5%) procedures and underestimated lesions (9%).     

Stereotactic vacuum-assisted breast biopsy: results, follow-up and correlation with radiological suspicion

PURPOSE: The purpose of this study was to assess the accuracy and clinical usefulness of stereotactic vacuum-assisted biopsy (VAB) for diagnosing suspicious, nonpalpable, only mammographically detectable breast lesions. MATERIALS AND METHODS: We retrospectively evaluated the results of percutaneous stereotactic VAB with 11-gauge needles performed over a period of 34 months on 228 nonpalpable suspicious breast lesions detectable on mammography only [Breast Imaging Reporting and Data System (BI-RADS) 3: 25.9%; BI-RADS 4: 67.1%; BI-RADS 5: 7%]. The imaging histological concordance was ascertained for each lesion. In cases of discordance, repeat biopsy or surgical excision were recommended; in cases of benign lesions, we urged a follow-up of at least 6 months and for borderline and malignant lesions a surgical excision. We also evaluated concordance between VAB results and subsequent examinations (surgical excision or followup). RESULTS: VAB demonstrated 123 (54%) benign lesions (with six cases of imaging-histological discordance), 26 (11.4%) borderline lesions and 79 (34.6%) malignant lesions. We obtained a suitable post-VAB mammographic or histological evaluation for 78 benign lesions, 17 borderline lesions and 76 malignant lesions, with one (1.3%) false negative (FN) case, two (11.8%) underestimations of borderline lesions, 14 (18.4%) underestimations of malignant lesions and no (0%) false positive cases. We did not observe any postbiopsy complications or scars. CONCLUSIONS: Percutaneous histological VAB with an 11-gauge needle proved to be, as reported in previous studies, a reliable method for diagnosing nonpalpable, mammographically detectable only breast lesions, with an underestimation rate lower than core biopsy and a FN rate similar to that of surgical biopsy, without any significant complications.     

Sonographically Guided Core Biopsy of the Breast: Comparison of 14-Gauge Automated Gun and 11-Gauge Directional Vacuum-Assisted Biopsy Methods

Objective

To compare the outcomes of 14-gauge automated biopsy and 11-gauge vacuum-assisted biopsy for the sonographically guided core biopsies of breast lesions.

Materials and Methods

We retrospectively reviewed all sonographically guided core biopsies performed from January 2002 to February 2004. The sonographically guided core biopsies were performed with using a 14-gauge automated gun on 562 breast lesions or with using an 11-gauge vacuum-assisted device on 417 lesions. The histologic findings were compared with the surgical, imaging and follow-up findings. The histologic underestimation rate, the repeat biopsy rate and the false negative rates were compared between the two groups.

Results

A repeat biopsy was performed on 49 benign lesions because of the core biopsy results of the high-risk lesions (n = 24), the imaging-histologic discordance (n = 5), and the imaging findings showing disease progression (n = 20). The total underestimation rates, according to the biopsy device, were 55% (12/22) for the 14-gauge automated gun biopsies and 36% (8/22) for the 11-gauge vacuum-assisted device (p = 0.226). The atypical ductal hyperplasia (ADH) underestimation (i.e., atypical ductal hyperplasia at core biopsy and carcinoma at surgery) was 58% (7/12) for the 14-gauge automated gun biopsies and 20% (1/5) for the 11-gauge vacuum-assisted biopsies. The ductal carcinoma in situ (DCIS) underestimation rate (i.e., ductal carcinoma in situ upon core biopsy and invasive carcinoma found at surgery) was 50% (5/10) for the 14-gauge automated gun biopsies and 41% (7/17) for the 11-gauge vacuum-assisted biopsies. The repeat biopsy rates were 6% (33/562) for the 14-gauge automated gun biopsies and 3.5% (16/417) for the 11-gauge vacuum-assisted biopsies. Only 5 (0.5%) of the 979 core biopsies were believed to have missed the malignant lesions. The false-negative rate was 3% (4 of 128 cancers) for the 14-gauge automated gun biopsies and 1% (1 of 69 cancers) for the 11-gauge vacuum-assisted biopsies.

Conclusion

The outcomes of the sonographically guided core biopsies performed with the 11-gauge vacuum-assisted device were better than those outcomes of the biopsies performed with the 14-gauge automated gun in terms of underestimation, rebiopsy and the false negative rate, although these differences were not statistically significant.     

MR imaging-guided 10-gauge vacuum-assisted breast biopsy: histological characterisation

Purpose

The aim of this study was to evaluate a handheld vacuum-assisted device for magnetic resonance imaging (MRI)-guided breast biopsy.

Materials and methods

In 47 patients, a total of 47 suspicious breast lesions (mean maximum diameter 9 mm) seen with MRI (no suspicious changes on breast ultrasound or mammography) were sampled using a 10-gauge vacuum-assisted breast biopsy (VAB) device under MRI guidance. Histology of biopsy specimens was compared with final histology after surgery or with follow-up in benign lesions.

Results

Technical success was achieved in all biopsies. Histological results from VAB revealed malignancy in 15 lesions (32%), atypical ductal hyperplasia in four lesions (8%) and benign findings in 28 lesions (60%). One of four lesions with atypical ductal hyperplasia was upgraded to ductal carcinoma in situ after surgery. One of seven lesions showing ductal carcinoma was upgraded to invasive carcinoma after surgery. Two lesions diagnosed as infiltrating carcinoma by VAB were not validated at excisional biopsy due to complete removal of the lesion during the procedure. During the follow-up (mean 18 months) of histologically benign lesions, we observed no cases of breast cancer development. Because of morphological changes on follow-up MRI scans, two lesions underwent surgical excision, which confirmed their benign nature. Besides minor complications (massive bleeding, n=1) requiring no further therapeutic intervention, no complications occurred.

Conclusions

MRI-guided biopsy of breast lesions using a handheld vacuum-assisted device is a safe and effective method for the workup of suspicious lesions seen on breast MRI alone.     

Breast masses: removal of all US evidence during biopsy by using a handheld vacuum-assisted device--initial experience

PURPOSE: To assess the effects of removal of all ultrasonographic (US) evidence of breast lesions by using a vacuum-assisted biopsy (VAB) device. MATERIALS AND METHODS: Thirty-four women with breast masses underwent US-guided biopsy with an 11-gauge VAB device, with which removal of all evidence of the lesion was attempted. Histologic findings were compared with results of surgery and follow-up imaging. Patient tolerance and perceptions of the procedure and the ability of the procedure to eliminate a palpable finding were evaluated with questionnaires and findings at follow-up physical examination. RESULTS: The biopsy protocol was completed in all cases. Twenty-six benign lesions (76%) and eight malignancies (24%) were diagnosed. After VAB, 10 patients (29%) underwent surgery on the basis of histologic findings of invasive carcinoma (n = 7), ductal carcinoma in situ (n = 1), lobular neoplasia (n = 1), or atypical ductal hyperplasia (n = 1). VAB resulted in complete excision of four of 10 lesions: two of eight malignancies and two of two benign lesions. Among 21 patients with benign lesions who underwent 6-month follow-up imaging, eight (38%) had a definite residual mass. At 6-month follow-up examination, VAB was seen to have eliminated the palpable abnormality in seven (88%) of eight patients with initially palpable benign masses. Thirty-two patients (94%) described no or mild pain during biopsy, and 33 patients (97%) rated care as excellent. CONCLUSION: After removal of all US evidence of breast masses with a VAB device, there was a substantial probability that residual lesion that was not visualized during the procedure would later be found at surgery or follow-up imaging. A palpable mass (< or =1.2 cm in mean diameter) was eliminated in 88% of cases, and patient tolerance and perceptions of the procedure were favorable.     

Diagnostic Performance of Core Needle Biopsy for Characterizing Thyroidectomy Bed Lesions

ObjectiveThyroidectomy bed lesions frequently show suspicious ultrasound (US) features after thyroid surgery. Fine-needle aspiration (FNA) may not provide definitive pathological information about the lesions. Although core-needle biopsy (CNB) has excellent diagnostic performance in characterizing suspicious thyroid nodules, no published studies have evaluated the performance of CNB specifically for thyroidectomy bed lesions. Therefore, we aimed to evaluate the diagnostic performance and safety of CNB for characterizing thyroidectomy bed lesions.Materials and MethodsA total of 124 thyroidectomy bed lesions in 113 patients (79 female and 34 male; age, 23–85 years) who underwent US-guided CNB between December 2008 and December 2020 were included. We reviewed the US imaging features of the target lesions and the histories of previous biopsies. The pathologic results, diagnostic performance for malignancy, and complications of CNB were analyzed.ResultsAll samples (100%) obtained by CNB were adequate for pathological analysis. Pathological analysis revealed inconclusive results in two lesions (1.6%). According to the reference standard, 50 lesions were ultimately malignant (40.3%), and 72 were benign (58.1%), excluding the two inconclusive lesions. The performance of CNB for diagnosing malignant thyroidectomy bed lesions in the 122 lesions had a sensitivity of 98.0% (49/50), a specificity of 100% (72/72), positive predictive value of 100% (49/49), and negative predictive value of 98.6% (72/73). Eleven lesions were referred for CNB after prior inconclusive FNA results in thyroidectomy bed lesions, for all of which CNB yielded correct conclusive pathologic diagnoses. According to the pathological analysis of CNB, there were various benign lesions (58.9%, 73/124) besides recurrence, including benign postoperative lesions other than suture granuloma (32.3%, 40/124), suture granuloma (15.3%, 19/124), remnant thyroid tissue (5.6%, 7/124), parathyroid lesions (4%, 5/124), and abscesses (1.6%, 2/124). No major or minor complications were associated with the CNB procedure.ConclusionUS-guided CNB is accurate and safe for characterizing thyroidectomy bed lesions.     

MR-guided vacuum-assisted breast biopsy in the management of incidental enhancing lesions detected by breast MR imaging

Purpose

The objective of this study was to determine the clinical value and accuracy of magnetic resonance (MR)-guided vacuum-assisted breast biopsy (VAB).

Materials and methods

We retrospectively analysed 106 incidental breast lesions detected on MR imaging in 98 patients. Patients with nonpalpable suspicious lesions that were only MR visible were referred for MR-VAB performed with a 10-gauge needle. All patients with a VAB diagnosis of infiltrating carcinoma, carcinoma in situ or atypical epithelial hyperplasia were referred for surgery. Histopathology of the surgical specimen was considered the reference standard.

Results

MR-guided VAB was attempted in 29/106 lesions (27%); in 2/29 patients, the procedure could not be performed owing to failure to visualise the lesion. Lesions with clearly malignant features and borderline lesions (atypical ductal hyperplasias) were identified in 12 cases (44%) and benign entities in 15 (56%). Seven of 12 (58%) malignant lesions were <10 mm. Among the 27 successful MR-VAB procedures, VAB yielded one false-negative diagnosis (4%) and underestimation (4%). MR-guided VAB sensitivity and specificity were 92% and 100%, respectively, with a positive predictive value of 100% and a negative predictive value of 93%.

Conclusions

The results of this study indicate that MR-guided VAB offers good accuracy in characterising nonpalpable breast lesions visible on MR imaging alone. Small lesion size (<1 cm) did not prove to be a limitation for the success of the procedure.     

Percutaneous CT-guided multisampling core needle biopsy of thoracic lesions

OBJECTIVE: The purpose of our study was to evaluate the diagnostic yield and the complication rate of percutaneous CT-guided coaxial 18-gauge (1.25-mm diameter) multisampling (five samples) core needle biopsy (CNB) of suspected thoracic lesions. MATERIALS AND METHODS: The records of 75 consecutive patients (29 women, 46 men; age range, 33-92 years) who underwent percutaneous CT-guided adjustable coaxial 18-gauge multisampling (five samples) CNB of a suspected thoracic lesion (eight mediastinal lesions, two chest wall lesions, two pleural lesions, and 63 intrapulmonary lesions) were reviewed. RESULTS: Ninety-seven percent (73/75) of CNB specimens were considered adequate for a specific diagnosis by the histopathology staff. Diagnostic yield was 97% (95% confidence interval, 91-99%) (72/74) (number of correct diagnoses obtained at CNB / number of definitive diagnoses). There were 61 malignant lesions and 11 benign lesions. There was no false-negative result when CNB was considered adequate for a specific diagnosis by the histopathology staff. Pneumothorax occurred in 19% (12/63 intrapulmonary lesions). One patient required placement of a chest tube. Minor postbiopsy hemoptysis occurred and resolved spontaneously in 11% (7/63) of patients. CONCLUSION: Percutaneous CT-guided coaxial multisampling large CNB of suspected thoracic lesions, in a mainly cancer-based population, is an accurate procedure for a specific histologic diagnosis and has a low rate of complications.